Risk factors associated with a second primary lung cancer (SPLC) in patients (pts) with a previous initial primary lung cancer (IPLC).
Misako Nagasaka(University of California, Irvine), Antoinette J. Wozniak(Wayne State University), Hirva Mamdani(Wayne State University), Kimberly Belzer(The Barbara Ann Karmanos Cancer Institute), Mary Ann Milczuk(Wayne State University), Seongho Kim(Wayne State University), Ann G. Schwartz(The Barbara Ann Karmanos Cancer Institute), Dina Farhat(The Barbara Ann Karmanos Cancer Institute), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 0
Related Papers
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3)
|JNCI Cancer Spectrum|2020|163
Familial Aggregation of Common Sequence Variants on 15q24-25.1 in Lung Cancer
|JNCI Journal of the National Cancer Institute|2008|152